Our group recently showed that at baseline, gene expression of ECM molecules is significantly lower in atrophic compared to nonatrophic patients with COPD for collagen type I, fibronectin, tenascin C, biglycan and PAX7 [11]. This evidence concerns the gene FN1 and chronic obstructive pulmonary disease.